



EDITOR IN CHIEF

K. Sreekumaran Nair, MD, PhD

diabetes®

ASSOCIATE EDITORS

E. Dale Abel, MD, PhD

Sharon G. Adler, MD

Peter J. Dyck, MD

Thomas W. Gardner, MD, MS

Kathryn M. Haskins, PhD

Gökhan Hotamisligil, MD, PhD

Michael D. Jensen, MD, PhD

Anna Krook, PhD

Lawrence J. Mandarino, PhD

Braxton Mitchell, PhD

Jeffrey E. Pessin, PhD

James R. Sowers, MD

Lori Sussel, PhD

Adrian Vella, MD, FRCP

Nick Wareham, MBBS, PhD, FRCP, FFPHM

Fredric E. Wondisford, MD

CONSULTING EDITORS

Reza Abdi, MD

Nada A. Abumrad, PhD

Rocco Barazzoni, MD, PhD

Timothy J. Bartness, PhD

Dwaipayan Bharadwaj, PhD, FNASc

Andrew A. Butler, PhD

Wenhong Cao, MD

Andre Carpentier, MD, FRCP

Deborah J. Clegg, RD, PhD

Claudio Cobelli, PhD

Anne Cooke, DPhil, FMedSci

Gregory Cooney, PhD

John A. Corbett, PhD

Daniel J. Drucker, MD

Josephine M. Egan, MD,

MRCPI, FRCPI

Gian Paolo Fadini, MD, PhD

Mark Febbraio, PhD

Brian N. Finck, PhD

Simon J. Fisher, MD, PhD

Alessia Fornoni, MD, PhD

Maureen Gannon, PhD

Richard E. Gilbert, MBBS, PhD, FRCP

Benjamin Glaser, MD

Laurie J. Goodyear, PhD

Struan F.A. Grant, PhD

Eric Hajduch, PhD

Christian Herder, PhD, MSc

Michael Horowitz, MBBS, PhD, FRACP

Patrick B. Iynedjian, MD

Anton M. Jetten, PhD

Weiping Jia, MD, PhD

James D. Johnson, PhD

Fredrik Karpe, PhD, FRCP

Mark T. Kearney, MD, FRCP

Richard G. Kibbey, MD, PhD

Jae Bum Kim, PhD

Jason K. Kim, PhD

Jeonga Kim, PhD

James L. Kirkland, MD, PhD

Amira Klip, PhD

Yogish C. Kudva, MD

Tony K.T. Lam, PhD

Ian R. Lanza, PhD

Chih-Hao Lee, PhD

Sheldon E. Litwin, MD

Carey N. Lumeng, MD, PhD

Patrick E. MacDonald, PhD

L. Charles Murtaugh, PhD

Nicolas Musi, MD

Erik Näslund, PhD

Inga Prokopenko, PhD

Jerry Radziuk, PhD, MD, CM

Jun Ren, MD, PhD, FAHA

Erik A. Richter, MD, DMSci

Michael Roden, MD

Leslie S. Satin, PhD

Gary J. Schwartz, PhD

Masakazu Shiota, DVM, PhD

Kevin R. Short, PhD

Bart Staels, PhD

John M. Stafford, MD, PhD

Scott A. Summers, PhD

Farook Thameem, PhD

Michael I. Trenell, PhD

Antonio Vidal-Puig, MD, PhD

Matthias von Herrath, MD

Jianping Weng, MD, PhD

Adam Whaley-Connell, DO, MSPH

Jianping Ye, MD

Lori M. Zeltser, PhD

AMERICAN DIABETES ASSOCIATION OFFICERS

CHAIR OF THE BOARD

Janel L. Wright, JD

PRESIDENT, MEDICINE & SCIENCE

Samuel Dagogo-Jack, MD, FRCP

PRESIDENT, HEALTH CARE & EDUCATION

David G. Marrero, PhD

SECRETARY/TREASURER

Richard Farber, MBA

CHAIR OF THE BOARD-ELECT

Robin J. Richardson

PRESIDENT-ELECT, MEDICINE & SCIENCE

Desmond Schatz, MD

PRESIDENT-ELECT, HEALTH CARE & EDUCATION

Margaret Powers, PhD, RD, CDE

SECRETARY/TREASURER-ELECT

Lorrie Welker Liang

CHIEF EXECUTIVE OFFICER

Kevin L. Hagan

CHIEF SCIENTIFIC & MEDICAL OFFICER

Robert E. Ratner, MD, FACP, FACE



*The mission of the American Diabetes Association
is to prevent and cure diabetes and to improve
the lives of all people affected by diabetes.*



Mission Statement for *Diabetes*

Diabetes publishes original research about the physiology and pathophysiology of diabetes mellitus.

Submitted manuscripts can report any aspect of laboratory, animal, or human research. Emphasis is on investigative reports focusing on areas such as the pathogenesis of diabetes and its complications, normal and pathological pancreatic islet function and intermediary metabolism, pharmacological mechanisms of drug and hormone action, and biochemical and molecular aspects of normal and abnormal biological processes. Studies in the areas of diabetes education or the application of accepted therapeutic and diagnostic approaches to patients with diabetes are not published. More information about the journal can be found online at diabetes.diabetesjournals.org.

Copyright © 2015 by the American Diabetes Association, Inc. All rights reserved. Printed in the USA. Requests for permission to reuse content should be sent to Copyright Clearance Center at www.copyright.com or 222 Rosewood Dr., Danvers, MA 01923; phone: (978) 750-8400; fax: (978) 646-8600. Requests for permission to translate should be sent to Permissions Editor, American Diabetes Association, at permissions@diabetes.org.

The American Diabetes Association reserves the right to reject any advertisement for any reason, which need not be disclosed to the party submitting the advertisement.

Commercial reprint orders should be directed to Sheridan Content Services, (800) 635-7181, ext. 8065.

Single issues of *Diabetes* can be ordered by calling toll-free (800) 232-3472, 8:30 A.M. to 5:00 P.M. EST, Monday through Friday. Outside the United States, call (703) 549-1500. Rates: \$75 in the United States, \$95 in Canada and Mexico, and \$125 for all other countries.

Diabetes is available online at diabetes.diabetesjournals.org. Please call the numbers listed above, e-mail membership@diabetes.org, or visit the online journal for more information about submitting manuscripts, publication charges, ordering reprints, subscribing to the journal, becoming an ADA member, advertising, permission to reuse content, and the journal's publication policies.

PRINT ISSN 0012-1797

ONLINE ISSN 1939-327X

PRINTED IN THE USA

Periodicals postage paid at Alexandria, VA, and additional mailing offices.

AMERICAN DIABETES ASSOCIATION PERSONNEL AND CONTACTS

EDITORIAL OFFICE DIRECTOR
Lyn Reynolds

PRODUCTION MANAGER
Amy S. Gavin

MANAGING DIRECTOR, MEDIA SALES
Clare Liberis
cliberis@diabetes.org
(212) 725-4925, ext. 3448

PEER REVIEW MANAGER
Jane Castner

EDITORIAL MANAGERS
Nancy C. Baldino
Valentina Such

ASSOCIATE DIRECTOR, BILLING
& COLLECTIONS
Laurie Ann Hall

EDITORIAL OFFICE SECRETARIES
Raquel Castillo
Joan Garrett

TECHNICAL EDITOR
Oedipa Rice

DIRECTOR, MEMBERSHIP/
SUBSCRIPTION SERVICES
Donald Crowl

MANAGING DIRECTOR,
SCHOLARLY JOURNAL PUBLISHING
Christian S. Kohler

VICE PRESIDENT, CORPORATE ALLIANCES
Nancy Stinson Harris

ADVERTISING REPRESENTATIVES
The Jackson-Gaeta Group, Inc.
B. Joseph Jackson
bartjack@aol.com
Paul Nalbandian
pnalbandian4ada@aol.com
(973) 403-7677

DIRECTOR, SCHOLARLY JOURNAL
PUBLISHING
Heather Norton Blackburn

ADVERTISING MANAGER
Julie DeVoss Graff
jdevoss@diabetes.org
(703) 299-5511

ISLET BIOLOGY—BETA CELL—DEVELOPMENT AND POSTNATAL GROWTH

motoxylol/eosin and anti-insulin/glucagon/amyloid). Representative images of the stained sections and accompanying morphological evaluation will be uploaded on the IIDP website. Investigators may request histology sections for their research. Further, IIDP requires center reporting of Islet Index (reflects islet size distribution), purity (dithizone staining), viability (inclusion/exclusion dyes), sterility (aerobic, anaerobic, fungal and sentinel tests) and potency (Glucose Stimulated Insulin Secretion (GSIS) assay). Since January 2010, 112.3 million human islets have been distributed. The mean properties of pure and impure broadcasts respectively are as follows: Islet Index 1.2, 1.1; % Purity 85.3, 53.3; % Viability, 92.0, 89.5; Potency-Stimulation Index, 3.0, 2.7; Sterility, 99.1% of broadcasts were sterile. To further enhance the program, the IIDP is currently evaluating the isolation of islets from type 1 diabetic (T1D) donors. Offers for pancreata from T1D donors are rare and retrievable Islet Equivalents (IEQ), can be limited. However, the IIDP recently succeeded in distributing 60,000 IEQs from a T1D child isolated at University of Pennsylvania to 10 investigators for critical T1 research.

Supported By: National Institutes of Health

2924-PO

Glutathione's Reduced Form Protects Beta Cells from Destruction Caused by Diabetogenic Ligands

GABIT G. MEYRAMOV, KLAUS-DIETER . KOHNERT, AISULU A. KIKIMBAEVA, OLIVIA-NEZRYN J. DUPONT, AIDAR M. AITKULOV, ZAURE T. KYSTAUBAEVA, GULMIRA M. TYKEZHANOVA, LUDMILA G. TURGUNOVA, ELENA M. LARYUSHINA, AIZHAN G. ABDRAIMOVA-MEYRAMOVA, GULMIRA O. ZHUZBAEVA, ALTYNAL S. SHAYBEK, KARLIGASH A. ZHUMASHEVA, SAYAGUL S. TYRSHANOVA, *Karaganda, Kazakhstan, Karlsburg, Germany, Astana, Kazakhstan*

Glutathione Reduced form contain SH-group (GSH) possess ability to bind- ing with ligands.

Aim of work: To study effect of GSH on action of diabetogenic zincbinding ligands Diphenylthiocarbazon (DZ) and 8-para (toluenesulfonylamino) quino- line (8PTSQ). Groups of rabbits: 1) injection of DZ 49.3-50.8 mg/kg 2) GSH 970-1020 mg/kg +DZ 48.9-51.6 mg/kg 10 min later; 3) GSH 985-1010 mg/kg+8PTSQ 47, 5-49, 7 mg/kg; 4) Glutathione Oxidized form (GOx) 980-1015 mg/kg+DZ 50, 9-51, 6 mg/kg. Blood Glucose level (BG)-3 times per 6 days. Other animals killed 10 min past 2nd injection.

Histology: aldehydefuchsin method; insulin immunohistochemistry (IG); vital by DZ and 8PTSQ staining of Zn²⁺-ions in B-cells with measuring of absorbance past injection of DZ (DZA) and 8PTSQ (IF).

Results: Group 1: BG: 5.4±0.7 mM before and 16.2±2.5 mM 6 days later; histology: necrosis and destruction of 85-90% B-cells; IG 1.07 ±0.03 (intacts-1.89±0.04); 2 animals early killed: binding of almost all amount of Zn²⁺-ions in B-cells by DZ: DZA 1.95±0.04 (intacts-1.00±0.02). Group 2: BG: 5.2±0.5 mM before and 6.2±0.6 mM 6 days later; histology: islets without changes; 3 animals early killed: binding of 7-12% of Zn²⁺-ions in B-cells: DZA 1.09±0.02 (intacts-1.00±0.03). Group 3: BG: 5.5 ±0.7 mM before and 6.8±0.9 mM 6 days later; histology: not marked necrobiosis in 5-10% of B-cells; 3 animals early killed: binding of 5-10% of Zn²⁺-ions in B-cells by 8PTSQ: IF 1.12±0.03 (intacts-1.97±0.07). Group 4: BG: 4.8±0.5 mM before and 14.8±2.6 mM 6 days later; histology: necrosis and destruction of 80-85% B-cells; IG 1.09±0.02 (intacts-1.87±0.05); 2 animals early killed: binding of almost all amount of Zn²⁺-ions in B-cells by DZ: DZA 1.92±0.05 (intacts-1.00±0.03).

Conclusions: 1) GSH protect B-cells of binding Zn²⁺-ions by diabetogenic ligands, of destruction B-cells and of developing diabetes; 2) GOx not contain SH-group, not protect Zn²⁺-ions in B-cells of binding by DZ that result destruction of cells and of developing of diabetes.

Supported By: Family of Professor Gabit G. Meyramov

ISLET BIOLOGY—BETA CELL—DEVELOPMENT AND POSTNATAL GROWTH

2925-PO

Single-Cell RNA-Seq Reveals Alpha-Cell Maturation Stages in Pancreas Development

DIANA E. STANESCU, KYOUNG JAE WON, DORIS A. STOFFERS, *Philadelphia, PA*

The heterogeneous nature of the developing pancreatic epithelium and the low abundance of endocrine progenitors limits the information derived from traditional expression studies. The advent of single-cell transcriptomics allows the identification of important differences between cells otherwise sorted together using lineage markers. To characterize the transcriptomic landscape of pancreatic endocrine cells we performed single-cell RNA-seq of e13.5 mouse pancreata using Fluidigm C1. 76 individual libraries were generated. The data were analyzed by Monocle to sort cells in an order accord-

ing to their progression through differentiation and to identify differentially expressed genes. Four cell states were identified: two appear to be early and terminal developmental stages, and two may represent intermediate stages. Glucagon (Gcg) was the major differentially expressed gene across the Monocle pseudo-differentiation stages, suggesting that Gcg+ cells at e13.5 are in different stages of maturation. A set of 152 genes had a similar expression profile to Gcg. Gene ontology (GO) analysis of this set showed enriched terms such as "cytoplasmic membrane-bounded vesicle" and "signaling and peptide hormone processing." Cells with very high Gcg transcript expressed other pancreatic hormones (insulin, ghrelin, peptide YY), albeit at lower levels, indicating that plurihormonal expression is a normal developmental stage in the maturation of α cells. Overall, Gcg+ cells expressed a variety of pro-endocrine factors (Sox9, MafB, Ngn3, Nkx2.2, FoxA2, Rfx6), and acinar lineage factors (Nr5a2, Rbpj, Cpa1, Gata4). At least at a transcriptional level, mouse pancreatic epithelial cells at e13.5 can concurrently express factors specific to different cell fates. Our study brings a new awareness of the maturational heterogeneity of mouse pancreatic endocrine cells at e13.5. It establishes the utility of single-cell RNA-Seq as an unbiased tool for analyzing pancreatic endocrine progenitors.

2926-PO


S 100-Positive Cells in the Human Islets of Langerhans

ALEXANDRA E. PROSHCHINA, YULIYA S. KRIVOVA, VALERIY P. CHERNIKOV, VALERIY M. BARABANOV, SERGEY V. SAVELIEV, *Moscow, Russian Federation*

The current studies suggest that in the pancreas the structures of the nervous system are the primary target of the autoimmune attack in diabetes type one (DM1). Experiments on NOD (nonobese diabetic) mice have revealed an autoimmunization against neuronal and glial cell antigens (S-100, GFAP, GAD) at early stages of DM1. In order to characterize cells containing S 100-like immunoreactivity in the islets of Langerhans, we examined the autopsied pancreatic specimens from human fetuses, infants and adults using immunohistochemistry and electron microscopy. Two types of S 100-positive cells, which differ in shape and localization, were detected in the human islets of Langerhans.

Small oval, spindle or triangular cells with processes were revealed on the margin of the islets. The glial nature of these cells was confirmed by electron microscopy. In the fetal and children's pancreata, glial cells were often seen in the forming pancreatic islets. It has been suggested that these cells are a part of neuro-insular complexes and may be involved in the pancreatic islets morphogenesis.

S 100-positive cells, which were similar in shape and localisation with other endocrine cells, were found within the islets. We propose that these cells may play a role in synchronization of islets calcium-dependent hormone release. These findings suggest novel neural-islet regulatory mechanism and therefore advance basic knowledge of islet neurobiology.



Supported By: Russian Foundation for Basic Research (15-04-03155)